In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...
Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...
The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...
In the exploratory subgroup analysis of chRCC by PD-L1 CPS status, there was a trend favoring nivolumab plus ipilimumab for ...
Dr. Ma emphasized that intratumor mycobiome dysbiosis is correlated with Clear Cell Renal Cell Carcinoma (ccRCC). He presented findings from an analysis of fungal communities in ccRCC, using ...
Dr. Simsek began by emphasizing that their group had previously shown that CD8+ T cells expressing PD-1 but lacking TIM-3 or LAG-3 are associated with improved clinical outcomes to anti–PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback